<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543436</url>
  </required_header>
  <id_info>
    <org_study_id>P 160910J</org_study_id>
    <secondary_id>2017-001257-14</secondary_id>
    <nct_id>NCT03543436</nct_id>
  </id_info>
  <brief_title>Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections</brief_title>
  <acronym>TEMO-CARB</acronym>
  <official_title>Temocillin Versus a Carbapenem as Initial Intravenous Treatment for Extended-spectrum Beta-lactamase Related Urinary Tract Infections, a Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French National Network of Clinical Research in Infectious Diseases (RENARCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TEMO-CARB is a phase 3, randomized, controlled, multicentre, open-label pragmatic clinical
      trial to test the non-inferiority of temocillin versus carbapenem as initial intravenous
      treatment of Urinary Tract Infection (UTI) due to extended-spectrum beta-lactamase (ESBL)
      producing enterobacteriaceae.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary tract infections are among the most common bacterial infections that are treated in
      the community by an empirical antibiotic treatment regimen. Enterobacteriaceae are the most
      common bacteria involved in urinary tract infection. Since 2006, extended-spectrum
      beta-lactamase (ESBL) producing enterobacteriaceae have spread in France, as elsewhere.
      Finding therapeutic alternatives to carbapenems in infections caused by ESBL producing
      enterobacteriaceae is imperative. Although temocillin, 6-α-methoxy derivative of ticarcillin
      has been suggested as a potential alternative to carbapenem therapy for ESBL related
      infections, it was not investigated in accordance with current standard. The hypothesis to
      test in this study is that temocillin is not inferior to a carbapenem as initial intravenous
      treatment of urinary tract infections caused by ESBL producing enterobacteriaceae.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and microbiological cure</measure>
    <time_frame>5-7 days after end of treatment</time_frame>
    <description>The primary endpoint, was defined as achieving both clinical cure and microbiological eradication of all baseline pathogens 5-7 days after completion of treatment.
Clinical cure is defined as complete resolution, substantial improvement or return to pre-infections signs and symptoms of complicated lower urinary tract infections or pyelonephritis without the need for additional antibiotic therapy Microbiological efficacy will be assessed by quantitative urine culture and defined as follows &lt; 10^3 Colony Forming Unit (CFU)/mL of the baseline pathogens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early microbiological eradication</measure>
    <time_frame>3-4 days after randomization</time_frame>
    <description>Microbiological eradication will be assessed by quantitative urine culture and defined as follows &lt; 10^3 colony forming unit Colony Forming Unit (CFU)/mL of the baseline pathogens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of oral antibiotic switch in both arms (temocillin vs. carbapenem)</measure>
    <time_frame>60 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Time from randomization to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent cure rate</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Clinical cure is defined as complete resolution, substantial improvement or return to pre-infections signs and symptoms of complicated lower urinary tract infections or pyelonephritis without the need for additional antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical recurrences</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Relapse: new symptoms of urinary tract infection in a patient previously considered as clinically or microbiologically cured in the visit 5-7 days after treatment completion plus positive urine ± blood culture grows the same microorganism isolated that in the initial culture.
Re-infection: same definition but with different strain in urinary culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Death for any reason or for infectious events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of temocillin according to kidney function</measure>
    <time_frame>3 days after treatment initiation</time_frame>
    <description>Description of the temocillin plasma concentration and its variability among patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota impact study</measure>
    <time_frame>Time Frame : 5-7 days after treatment completion</time_frame>
    <description>Study treatment impact in the gut colonization with multidrug Gram negative bacilli) and temocillin resistant Gram negative bacilli</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Intravenous temocillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous meropenem or imipenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temocillin</intervention_name>
    <description>Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .</description>
    <arm_group_label>Intravenous temocillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem or imipenem</intervention_name>
    <description>Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)</description>
    <arm_group_label>Intravenous meropenem or imipenem</arm_group_label>
    <other_name>Carbapenems</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (≥ 18 years)

          -  Hospitalized patient with clinically significant monomicrobial UTI

          -  Complicated UTI due to ESBL producing enterobacteriaceae (pyelonephritis, prostatitis
             or renal abscess) requiring parenteral antimicrobial therapy

          -  Susceptibility to temocillin and carbapenem as evidenced by testing results

          -  For woman able to procreate: negative pregnancy test and use of an effective method of
             contraception (abstinence, oral contraceptives, intra-uterine device, diaphragm with
             spermicide and condom). All forms of hormonal contraception are acceptable

          -  Signed informed consent by patient himself (able or under curatorship) or his legal
             representative (patient unable to give his consent or under tutorship)

          -  Patient affiliated to the social security system

        Exclusion Criteria:

          -  Patient infected with a bacteria which is not an ESBL-producing enterobacteriaceae.

          -  Polymicrobial infection.

          -  Hypersensitivity and/or previous intolerance to carbapenem or temocillin, or
             penicillins or any other beta-lactam.

          -  Patient with a contraindication to any of the drugs to be used in research

          -  Patient presenting another site of infection than urinary (except onset of bacteraemia
             from urinary tract origin due to Gram negative bacteria).

          -  Woman who is pregnant, breastfeeding, or expecting to conceive at any time during the
             study (pregnancy test will be conducted for woman without menopause).

          -  Palliative care of life expectancy &lt; 90 days.

          -  Ongoing empirical treatment of the urinary tract infections with carbapenem or
             temocillin &gt; 24 hours before randomization

          -  Delay in randomization &gt; 48 hours after identification of ESBL producing
             enterobacteriaceae in urinary and/or blood culture.

          -  Participation in other clinical trial for the infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit PILMIS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier LORTHOLARY, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit PILMIS, MD</last_name>
    <phone>+33-(0)1-42-19-26-63</phone>
    <email>bpilmis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prissile BAKOUBOULA, PhD</last_name>
    <phone>+33 1 71 19 64 94</phone>
    <email>prissile.bakouboula@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort-de-france</city>
        <state>Martinique</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marie TURMEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Severine ANSART, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Paul STAHL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melun Hospital - CHU Sud</name>
      <address>
        <city>Melun</city>
        <zip>77</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sylvain DIAMANTIS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Solenn KERNES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Necker-Enfants maladies Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier LORTHOLARY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit PILMIS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier LESCURE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vanina MEYSSONIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruxandra CALIN, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Beaujon Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victoire DELASTOURS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Georges Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David LEBEAUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laure SURGERS, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Joseph Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit PILMIS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles DUMONDIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Blandine RAMMAERT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marion BALDEYROU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-inferiority study</keyword>
  <keyword>Temocillin</keyword>
  <keyword>Carbapenem</keyword>
  <keyword>ESBL infection</keyword>
  <keyword>Urinary tract infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Temocillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

